N eurotransmitter receptors are essential for mediating the effects of neurotransmitters in the brain and peripheral nervous system. There are generally considered to be two types of neurotransmitter receptors: ionotropic and metabotropic. While ionotropic receptors are typically ligand-gated ion channels, through which ions pass in response to a neurotransmitter, metabotropic receptors need G proteins and second messengers to indirectly modulate ionic activity in neurons. G protein-coupled receptors (GPCRs) represent the largest family of metabotropic receptors, although receptor tyrosine kinases 1 and guanylate cyclase receptors 2, 3 can also be considered metabotropic receptors 4 . GPCRs also constitute the largest family of druggable targets 5, 6 encoded by the human genome, and 34% of medications approved by the US Food and Drug Administration have GPCRs as their main therapeutic target 7, 8 , especially those used for the treatment of neuropsychiatric disorders 6, 9, 10 (Table 1 ). There are many distinct chemical classes of neurotransmitters, including the following: (1) small molecules (e.g., glutamate, norepinephrine and serotonin); (2) neuropeptides (e.g., enkephalins, endorphins and neurokinins); and (3) others, including metabolites (e.g., endocannabinoids, ATP, ADP and adenosine) and gases (e.g., nitric oxide). Although the precise number of brain neurotransmitters is not known with certainty, it is likely that hundreds of distinct neurotransmitters exist, including many 'orphan' neuropeptides 11 . Each neurotransmitter system has distinct cellular and region-specific distribution patterns in the brain; these can be visualized at the mRNA level with the Allen Brain Atlas 12 or via genetically encoded markers with the GENSAT (Gene Expression Nervous System Atlas) resource 13 . Almost all neurotransmitters transduce their signals at least in part by activating GPCRs, and the regional and cellular distributions of brain GPCR mRNAs are well described 12, 14 . As is the case with neurotransmitters, each of the metabotropic receptors for neurotransmitters has a distinct regional and cellular distribution in the brain 12, 14 and elsewhere 14 . GPCRs modulate synaptic transmission via so-called 'slow synaptic transmission' 15 , which occurs in a time frame of seconds to minutes in the central nervous system. Metabotropic receptors such as GPCRs may be found pre-and post-synaptically. Pre-synaptic G i -coupled GPCRs, such as the 5-HT 1A and 5-HT 1B serotonin receptors 16, 17 , inhibit neurotransmitter release via Gβ/γ-mediated activation of inhibitory channels, such as G protein-coupled inwardly rectifying potassium channels 18 , and via the inhibition of vesicle-docking SNARE-like proteins 19, 20 ( Fig. 1) . Post-synaptically, GPCRs can enhance neuronal excitability via G s -and G q -coupled GPCRs, which have complex actions mediated by second messengers and protein kinases 21, 22 ( Fig. 1 ). This Review will discuss how structural insights into neurotransmitter GPCRs have transformed the understanding of these receptors, focusing on example GPCRs that are targets of drugs approved for use in the treatment of neuropsychiatric disorders. The past decade has witnessed remarkable progress in elucidating the structure and function of GPCR family, with perhaps 60 or so GPCRs having their structures determined by X-ray crystallography 7 or cryo-EM 7 . Additionally, various intermediate signaling states, ranging from inactive to active, have been elucidated for exemplar GPCRs 6 . Finally, progress has been made on the use of such structural information for structure-guided and structure-inspired neuropsychiatric drug discovery 8 . This Review will provide an overview of the understanding of how structure informs the function of representative neurotransmitter GPCRs. It will also show how an understanding of structure elucidates neuropharmacology and will highlight therapeutic challenges and opportunities for neurotransmitter-targeted GPCRs.
Structural genomics of neurotransmitter-targeted GPCRs
Structural genomics has been defined as the approach that proposes 'determining protein structures on a genome-wide scale' 23 , which boils down to ultimately determining the three-dimensional structure of every protein encoded by the human genome. Obtaining GPCR structures has been historically challenging. Thus, although low-resolution structures of rhodopsin were available as early as 1993 (ref. 24 ), and useful models of helical arrangements were generated through the use of that information 25 , the first bona fide high-resolution GPCR structure was not achieved until 2000, with rhodopsin 26 . The first non-opsin GPCR structures were obtained in 2007 (refs. [27] [28] [29] ), and since then, structures have been obtained, mainly via X-ray crystallography, for around 60 distinct human GPCRs 7 (Fig. 2a) . To generate useful structures, GPCR crystallography typically requires high-affinity ligands, which serve to stabilize the receptor in a distinct state suitable for crystallography. Such compounds not only need to be of high affinity (e.g., in the low nanomolar to picomolar range) but also need to have slow dissociation rates 30 . Ideally, then, to obtain complete structural coverage of all GPCRs encoded by the human genome, one would need highaffinity, slowly dissociating ligands for each of them. Such ligands do not necessarily need to be specific, as, for example, the nonselective drug ergotamine has been used to obtain the structures of three different serotonin receptor subtypes: 5-HT 1B (ref. 
32
) and 5-HT 2C (ref.
33
). Once structures are obtained, even with non-selective ligands, the structural features for distinct pharmacological properties can be elucidated (as in refs. 32, 33 ). Furthermore, obtaining structures of related GPCRs frequently facilitates the structure-guided discovery and design of subtype-selective drugs 34 . An analysis of available GPCR structures and cognate ligands, done with open-source databases of small molecules that bind known protein targets, along with databases of GPCR structural information, can be the first step toward determining the feasibility of a comprehensive structural elucidation of the 'GPCR-ome' . Chembl 35 , the KiDatabase 36 and PubChem 37 are databases that match compounds and their targets. Figure 2a shows the number of ligands with Chembl-annotated activity, plotted against a total of 393 non-olfactory GPCRs and, simultaneously, the number of structures available for each of these receptors (as of February 2019). Similar to previously published analyses [6] [7] [8] 38, 39 , in this analysis, around half of all human non-olfactory GPCRs are well annotated with respect to chemical matter, while the rest have few to no compounds associated with them in openly available databases 35 .
With one exception-the receptor FZD4 (Frizzled 4), for which the structure of the seven-transmembrane domain (TM7) in the ligand-free state has been solved 40 -those GPCRs for which there are reported structures typically have hundreds to thousands of annotated ligands (Fig. 2a) . No clear relationship exists between the number of annotated ligands in Chembl and the number of distinct structures (Fig. 2b) , although, as mentioned above, high-affinity, slowly dissociating ligands are typically key for obtaining structures. Thus, comprehensive elucidation of the structural genomics of GPCRs will require that suitable ligands be obtained for a large number of these receptors. Efforts are now ongoing to obtain these ligands, including the 'Illuminating the Druggable Genome' initiative (https://commonfund.nih.gov/idg), which has designated those GPCRs for which there is little chemical matter a top priority.
Taking into account the wealth of data noted above, and with new GPCR structures now appearing every week or so, what are the opportunities and challenges for the completion of a structural genomics survey for neurotransmitter GPCRs? Even for the 240 class A (Rhodopsin-like) GPCRs, which comprise most neurotransmitter receptors and for which there is the most structural coverage, fewer than 50 distinct members have elucidated structures. Several classes -B2 (Adhesion), C (Glutamate), F (Frizzled) and T [31] [32] [33] have published structures. Thus, considerable opportunities exist for obtaining structures of representative members of each neurotransmitter GPCR subfamily. Additionally, even for neurotransmitter receptor families such as the muscarinic receptor family, which has acetylcholine as its neurotransmitter and for which four (M1, M2, M3 and M4) [42] [43] [44] of five members have structures reported, the structural determinants for subtype selectivity are still to be elucidated and fully exploited for the creation of selective muscarinic agonists and antagonists 45 . For muscarinic receptors, in particular, it is clear that drugs targeting M1 and M4 muscarinic receptors may have special utility for the enhancement of cognition in Alzheimer's disease and schizophrenia, while interactions with M3 muscarinic receptors are associated with debilitating side effects 46, 47 . In terms of creating subtype-selective drugs, a variety of structure-guided approaches can be used, including targeting allosteric and orthosteric sites (as discussed in refs. 6, 8, 48 ). As the foregoing makes clear, although considerable progress has been made toward a comprehensive understanding of the structural genomics of human neurotransmitter GPCRs, a vast amount of work remains, which will require the integrated and coordinated efforts of structural biologists, pharmacologists, chemists and computational biologists.
Structural insights into activation and biased signaling
As with GPCR structural genomics, considerable insight into the structural features of neurotransmitter-targeted GPCR activation and biased signaling has been obtained. As for GPCR activation, the first structure of a GPCR in complex with hetereotrimeric G proteins was obtained in 2011 (ref. 49 ), and since then, several structures of nanobody-stabilized active states (e.g., β 2 adrenergic receptors 50 , M2 muscarinic receptors 51 and κ-and μ-opioid receptors 52, 53 ) and heterotrimeric G protein-stabilized active states (e.g., calcitonin receptors 54 , CGRP (calcitonin gene-related peptide) receptors 55, 56 , the 5-HT 1B serotonin receptor 57, 58 , μ-opioid receptors 59 and the GLP-1 (glucagon-like peptide-1) receptor 60 ) have appeared, essentially all with neurotransmitter-targeted GPCRs. Furthermore, structures of arrestin-biased agonists at the receptor 5-HT 2B (refs. 32, 61, 62 ), arrestin-bound rhodopsin 63 and G protein-biased agonists at the GLP-1 receptor 64 have been reported. Finally, there are inactive-state structures stabilized by sodium (e.g., A 2A adenosine receptors 65 , δ-opioid receptors 66 and D4 dopamine receptors 34 ), negatively modulating allosteric nanobodies at the β 2 adrenergic receptor 67 and the ligand-free basal structure of the receptor FZD4 40 . Figure 3 depicts representative structures of these various states, along with a graphical representation of an extended ternary complex model of receptor activation that includes complexes stabilized by both G protein 68 and β-arrestin
69
. The outward movement of TM6 is the hallmark for GPCR activation, as are several other canonical rearrangements 49, 53 . These include rearrangements of several microswitches 32 such as the 'P-I-F' motif, formed by residues P 5.50 , I
3.40 and F 6.44 (Fig. 4) . Here there is an inward shift of P 5.50 , along with a rotamer switch of I 3. 40 and a large inward movement of F 6.44 . Additional microswitches that undergo rearrangement include the D(E)/RY motif in TM3 and the NPxxY motif in TM7. The salt bridge between D 3.49 and R 3.50 is typically broken in active-state structures 49, 53 . At the NPxxY motif, activation reveals a rotation of Y 7.53 . Additionally the sodium site collapses due to rearrangements of key residues that coordinate sodium 53 (Fig. 4) . 18, 128 , and by inhibiting vesicle-release machinery, including SNARE proteins 19 . Post-synaptic G q -and G s -coupled GPCRs can induce or potentiate neuronal firing via varous intracellular second messengers 129 and secondary modulation of ion-channel activity 21 . PKA, protein kinase A. . In general, the 'active-like' receptor states in Fig. 3 show the various transitions mentioned above without the large outward movement of TM6.
Currently, there are two published structures of GPCRs in complex with β-arrestin-biased agonists, including LSD 70 and ergotamine 32 with the 5-HT 2B serotonin receptor, and one structure of a G protein-biased ligand in complex with hetereotrimeric G protein for the GLP-1 receptor 64 . The β-arrestin-biased agonist structures (Fig. 3) (Fig. 4a) .
Notably, Ser 7.45 rotates in to occlude the sodium pocket (Fig. 4a) . Additionally, a key residue (Leu209) in extracellular loop 2 (EL2) seems to form a 'lid' over LSD, retarding its dissociation and being essential for the recruitment of arrestin. A similar role for the same residue in EL2 was verified in studies of the D2 dopamine receptor and several other biogenic amine receptors 61, 62, 72 . Notably, the P-I-F and NPXXY motifs, along with conformational rearrangements in TM6 and TM7, are consistent with an intermediate activated state 61 ( Fig. 4b) . Collectively, these rearrangements suggest that concerted conformational changes involving residues throughout the receptor, although they do not fully mimic the changes in the rhodopsin-arrestin complex 63 , are responsible for the arrestin-biased conformation that favors binding of arrestin (Fig. 4b) . In contrast, the GLP-1 complex with the G protein-biased agonist exendin-P5 shows the most pronounced difference in TM1, along with extracellular regions of TM6, TM7 and extracellular loop 3 (EL3), for which there is support by extensive mutagenesis (details in ref. 64 ). The inactive states typically show a conserved sodium site, with sodium visualized in the structures of highest resolution 34, 65, 66 . Additionally, a conserved 'ionic lock' between D/E 3.49 (of the D(E)/ RY motif) and N 6.30 , which stabilizes the ground state of several GPCRs 73, 74 , is occasionally seen. Remarkably, in an inactive state stabilized by Nb60 (nanobody 60) and carazolol 67 , this ionic lock is recapitulated by the nanobody. Additionally, in many inactive-state structures, the P-I-F, NPxxY and D(E)/RY motifs are all in a generally conserved 'inactive-like' state.
The studies discussed above demonstrate clear progress in the understanding of the structural features required for different modalities of receptor activation and signaling. Clearly, much remains to be done in this direction, and the discovery of many novel permutations of these features is eagerly anticipated. 
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Fig. 3 | Structural validation of the extended ternary complex model of GPCR action.
The extended ternary complex model 6, 68, 69 predicts the existence of multiple interconvertible GPCR states stabilized by ligands (agonists, neutral antagonists and inverse agonists) and transducers (G proteins, arrestins and other transducers). The various high-resolution structures here have provided validation for this schema. These states include the following: inactive states stabilized by allosteric nanobodies (RL2) 67 ; active sodium-bound (R*L) 70 and inactive sodium-bound states 66 stabilized by agonists and inverse agonists, respectively; and coupled states (R*GL and R**LβArr). The model also provides for the possibility of biased signaling due to agonist-induced stabilization of distinct active and coupled states 31, 32 (e.g., R*L and R**L). Finally, spontaneously active states (R*) and coupled states (R*G), which have been demonstrated in many systems 68 , are predicted to exist, although structures of these are not yet available. βArr, β-arrestin. Each state for which a structure is known is presented with the Protein Data Bank accession code in parentheses directly above and a description of the structure at top. Here, * and ** represent distinct active and coupled states. 
Challenges and opportunities for drug design and discovery
Selectivity. Given the large number of GPCR structures and reasonable coverage of some GPCR families, these structures should, at least in theory, be useful for the de novo design of selective drugs. This is particularly true when new 'pockets' are discovered, as was the case for the D2 75 , D3 76 and D4 34 dopamine receptors. As shown in Fig. 5a -c, these structures revealed potentially unique binding surfaces that could be exploited for the design of selective ligands. Figure 5d shows a more detailed view of the D4 selectivity filter, while Fig. 5e shows how this is occluded in the D2 receptor 34 . Given that all three structures were obtained with chemically distinct and non-selective ligands, however, it is conceivable that the different binding pockets might simply reflect the fact that different ligands with distinct chemical scaffolds (e.g., different chemotypes) engage different residues in the receptors. One way to test the hypothesis that these different binding pockets are pharmacologically relevant is to create new ligands that are designed to engage these 'selectivity filters' . For the D3 receptor, remarkable success was achieved 77 with a compound with 1,700-fold selectivity for the D3 receptor and minimal off-target activity (Fig. 5) . Starting with the seed compound eticlopride (Fig. 5f ), which is a potent and nonselective D2 and D3 antagonist with weaker activity at D4, that group of researchers 77 used a combination of docking and medicinal chemistry to identify a potential modified scaffold predicted to target a putative selectivity region within the D3 receptor previously identified by mutagenesis and molecular modeling 76 (Fig. 5g) . Via this structure-inspired design approach, compound 19 ( Fig. 5g) was eventually synthesized and was found to be a potent and selective D3 antagonist.
An alternative approach is to target such 'selectivity filters' via automated docking (Fig. 5c-e,h) . In an initial proof-of-concept study, the D4 dopamine receptor selectivity filter was targeted by a docking screen of 600,000 commercially available compounds 34 from the ZINC database 78 . A set of 'seed' compounds discovered from the initial docking screen was further optimized by docking and subsequent identification of analogs; that ultimately led to the highly selective D4 partial agonist compound 9-6-24 34 , which was >1,000-fold selective for the D4 receptor and lacked activity at 320 other GPCRs.
Subsequent to that, the computational approach has been enhanced by automated docking-based screening of ultra-large libraries in a screen with 138 million drug-like compounds. This in silico screening, wherein each compound was docked in >100,000 conformations, required the analysis and scoring of 70 trillion docking events 79 (Fig. 5h) . In this study 79 , the previously identified D4 selectivity filter 34 composed of the pocket formed by residues Leu 3.28 and Phe 2.61 ( Fig. 5c-e) was again computationally targeted. That docking screen led to the discovery of a large number of chemically novel and highly selective D4 ligands. Of these, ZINC621433144 (Fig. 5h) was the most potent of the agonists tested, with a median effective concentration (EC 50 ) of 180 pM and selectivity for D4 over D2 and D3 (Fig. 5h) . On the basis of the rate of true positive results among the predicted active compounds, the authors estimate that as many as 400,000 distinct D4-active compounds with more than 70,000 diverse chemotypes 79 could exist in the library of 138 million compounds. Similar, albeit less computationally intensive, docking-based approaches have yielded selective ligands for the 5-HT 1B serotonin receptor 80 , κ-opioid receptor 81 , D2 dopamine receptor 81 and other receptors (reviews available in refs. 8, 82 ).
Structure-guided design of biased ligands
Functional selectivity, also known as 'biased signaling' 83 , has been defined as the process by which "...ligands induce (or stabilize) unique, ligand-specific receptor conformations…result(ing) in differential activation of signal transduction pathways associated with that particular receptor" 83 . The phenomenon of functional selectivity occurs when different ligands at the same receptor lead to ), in green (c). d, Location of the D4 selectivity filter, with nemonapride bound in green. e, The selectivity filter in d is occluded in the D2 receptor (D2 residues in magenta). f-h, As described in the text, the D3 receptor structure was used to modify the non-selective D3 inverse agonist eticlopride (f) to compound 19 (g), which has high affinity and selectivity. Alternatively, ultra-large scale docking led directly to ZINC621433144 (h) which emerged as a picomolar potent and selective D4 agonist 79 . Affinities for eticlopride are from ref. preferential activation of different G proteins (e.g., G protein-subtype bias), a preference for G-protein signaling over arrestin (e.g., G-protein bias) or a preference for arrestin signaling over G proteins (e.g., arrestin bias). Reports of functional selectivity at GPCRs have appeared for many decades (an example of this is in ref. 84 ), and such bias is now recognized as a nearly universal phenomenon for GPCRs 6 . Indeed, there are now multiple reports of the discovery and optimization of arrestin-biased ligands 85, 86 and G proteinbiased ligands [87] [88] [89] for many GPCRs (reviews available in refs. 6, 90, 91 ). As mentioned above, so far there is only one structure of a GPCR (a GLP-1 receptor) in complex with a G protein-biased ligand (peptide exendin-P5) and hetereotrimeric G proteins 64 , a handful of structures of arrestin-biased ligands in complex with the 5-HT 2B serotonin receptor 32, 62, 70 , and no structures of arrestin-biased ligands in a GPCR-arrestin complex. Thus, although there is a paucity of structural information on GPCR functional selectivity, there have been several reports in which structure-informed and structureinspired design of neurotransmitter-targeted G protein and arrestin-biased ligands have been achieved.
For example, the discovery of G protein-biased agonists for the μ-opioid receptor has been reported 92 , although this discovery was accomplished without knowledge of any of the structural features responsible for biased signaling. In that study, molecular docking of 3 million compounds was performed against the inactive conformation of the μ-opioid receptor targeting a highly conserved aspartic acid (Asp 3.32 ) and engaging a conserved water network and a tyrosine residue (Tyr 3.33 ) putatively involved in selectivity and agonist activity.
Compounds with predicted activity were tested for functional activity at G protein and arrestin signaling and, after several rounds of medicinal chemistry optimization, PZM21 was identified as a potent and efficacious G protein-biased agonist 92 . Similar G protein-biased ligands have been discovered for μ-opioid receptors 93, 94 and κ-opioid receptors 89, 95 , although these were not informed by structural determinants. On the other hand, via a combination of molecular dynamics and synthetic studies, a derivative of salvinorin A 96 was discovered for μ-opioid receptors 97 that is G protein biased and thus probably has less potential for abuse. Similarly, in a study of κ-opioid receptors, residues identified from structural studies as being essential for biased signaling ultimately led to the creation of novel structure-guided G protein-biased opioid agonists 52 . A structure-inspired approach 72 for the creation of biased ligands at aminergic GPCRs, all of which are essential targets for the neurotransmitters serotonin, norepinephrine, dopamine and histamine, proved successful as well. For this study 72 , the authors took advantage of prior studies indicating that interactions with TM5 serine and other residues are essential for G-protein signaling 62 at aminergic GPCRs, while interactions with EL2 residues can be essential for arrestin signaling 61 . Via a combination of molecular modeling, molecular dynamics simulations, automated docking and synthesis, the arrestin-biased compound 7 was discovered for the D2 dopamine receptor 72 ( Fig. 6a) . As previous studies have shown that such arrestin-biased compounds may have efficacy in the treatment of schizophrenia and related neuropsychiatric disorders 85, 98 , this could represent a useful approach for optimizing arrestin-biased medications for the treatment of neuropsychiatric disorders. Finally, it is also worth mentioning that biased signaling might be influenced at the level of recruitment of and receptor phosphorylation by GPCR kinases 99 , and that this potentially can be influenced by GPCR ligands.
Orphan and understudied GPCRs. As previously mentioned, nearly 50% of GPCRs, most of which are highly expressed in the brain 14 , have a paucity of known ligands. Even for those neurotransmitter receptors that have been the subject of intensive investigation, such as muscarinic and dopamine receptors, the identification of suitably selective ligands for the various subtypes continues to be challenging. Thus, for example, there are no truly selective agonists for D5 dopamine or M5 muscarinic receptors, although a modestly selective D5 antagonist 100 and a fairly selective M5 antagonist 101 have been reported. Unfortunately, off-target pharmacology has not been reported for these compounds, so their selectivity over other GPCRs is unknown. Although there are no published structures of orphan or understudied brain GPCRs (oGPCRs 38 ), the use of homology models and automated docking has provided a structure-inspired approach for ligand discovery. Thus, for example, an integrated approach using parallel screening, homology modeling, docking and analog synthesis led to ogerin -a selective positive allosteric modulator for GPR68 -and selective negative allosteric modulators for GPR65 102 (Fig. 6b) . The allosteric modulator ogerin was demonstrated to affect learning and behavior in mice, which indicates that GPR68 is a potentially important GPCR in the brain 102 . A similar approach led to the discovery of selective agonists for the oGPCR MRGPRX2, which is involved in pain and itch 103 and binds many important neurotransmitters, including 72 (details in text). Here, through the use of a combination of molecular dynamics simulations, docking and medicinal chemistry, compounds were created that were predicted to interact with a conserved EL2 residue that can impart arrestin bias. b, Computational strategy for the discovery of small-molecule probes with which to modulate oGPCRs such as GPR68 102 Here, 3.1 million compounds were docked to a model of GPR68 and then, via iterative docking and testing of analogs, ogerin was identified as a selective GPR68 positive allosteric modulator. . These approaches are facilitated by parallel screening approaches in which hundreds of oGPCRs can be screened simultaneously 102, 104 ; active compounds are used to inform homology models for docking and subsequent discovery of new ligands 102, 103, [105] [106] [107] . Genetic and model organism studies are also facilitating understanding of the potential therapeutic importance of oGPCRs for neuropsychiatric disease. Thus, a published study has indicates that the oGPCR MRGPRX4 is involved in the pain and itch sensations mediated by bile acids 108 Another study has shown that MRGPRX4 is also essential for the preference for menthol cigarettes in certain ethnic populations 109 . Given the distribution of MRGPRX4 in peripheral nerves, it is likely that MRGPRX4 and related receptors are neurotransmitter receptors involved in peripheral sensations such as pain and itch 110 . Databases devoted to the brain distribution of oGPCRs 39, 111, 112 should facilitate discovery of their endogenous neurotransmitters, their function and neuropsychiatric implications for pathogenesis and treatment.
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Polypharmacology. Historically, the most effective drugs for many complex neuropsychiatric diseases have targeted multiple GPCRs and other molecular targets 9, 113 . It is now understood that this is probably because of the exceedingly complex genetic landscape of common diseases in which hundreds to thousands of genes might exert small effects 114 . This has led to the understanding that complex diseases are omnigenic rather than polygenic 114 , meaning that nearly every gene may ultimately exert a small effect on core disease pathways. Perhaps not surprisingly, the desire to discover increasingly selective drugs has resulted in lower overall success rates of drug-discovery screens 115 . Such a lack of success has led to the hypothesis that generating polypharmacological drugs with designated multiple targets represents a useful approach for the treatment of complex diseases 113, 116 . For aminergic GPCRs, there has been some success in discovering the structural features responsible for polypharmacological activities 33 , which comprise a series of nine semi-conserved residues (Asp 3.32 6.52 and EL2 Val/Ile/Leu). Although in theory, structureguided approaches should be helpful for the discovery and design of polypharmacological drugs, so far, this has not been entirely successful 117, 118 therapeutic and commercial opportunities for structure-guided GPCR drug discovery Heptares (acquired by Sosei in 2016) 119 , and Receptos (acquired by Celgene in 2015) 120 , along with Conformetrix 121 , have invested considerable resources in bringing GPCR structure-guided drug discovery to fruition. So far, publicly available information indicates that the exemplar compounds are targeted mainly to well-studied GPCRs for which selective ligands are difficult to obtain. Thus, for example, Heptares has advanced an M4-selective agonist to phase I trials, presumably for cognition enhancement (https://clinicaltrials. gov/ct2/show/NCT03244228?term=heptares&rank=4). Heptares has also brought a structure-guided mGlu5 negative allosteric modulator 122 for metabotropic glutamate receptors to initial phase I trials, presumably for application to the central nervous system (https://clinicaltrials.gov/ct2/show/NCT03785054?term=heptare s&rank=2). Receptos, in partnership with Celgene, has advanced RPC1063, an S1P receptor agonist for the treatment of multiple sclerosis (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ detailedIndex.cfm?cfgridkey=611517), to phase III clinical trials.
Future directions
Given the wealth of structural information now available for many GPCRs, it is anticipated that structure-guided approaches will eventually lead to neuropsychiatric medications with greater efficacy and fewer side effects. As on-target and off-target side effects, along with clinical effectiveness and safety, continue to be major drivers of drug failures in clinical trials 123 , insights into the structural basis of ligand engagement could provide new opportunities for GPCR-based neuropsychiatric drug discovery. Thus, where a G protein-biased ligand might show greater efficacy and fewer side effects, insights into the structural basis of such bias could accelerate the discovery of novel chemotypes with biased signaling patterns. Indeed, this approach has been successful in the generation of biased tool compounds for many neurotransmitter receptors, including D4 dopamine receptors 34, 124 , μ-opioid receptors 92 and other receptors 62, 72 . Although there are currently no structureguided biased drugs in clinical trials, encouraging results have appeared for TRV130 as a G protein-biased opioid receptor agonist for pain 125 , albeit with some abuse liabilities, as manifested in preclinical studies 126, 127 . As is clear from the foregoing, the past decade has witnessed astounding progress in understanding of the structure and function of metabotropic receptors for neurotransmitters. This increasing wealth of structural information, as well as advances in structure-guided and structure-inspired drug discovery, promise to accelerate the discovery of drugs that target metabotropic receptors for neurotransmitters with improved efficacies and fewer side effects.
